Inhibition of prothrombin kringle-2-induced inflammation by minocycline protects dopaminergic neurons in the substantia nigra in vivo

NeuroReport

Volumn 25, Issue 7, 2014, Pages 489-495

  Nam, Jin Han ^a   Leem, Eunju ^c   Jeon, Min Tae ^c   Kim, Young Je ^c   Jung, Un Ju ^c   Choi, Myung Sook ^c   Maeng, Sungho ^b   Jin, Byung Kwan ^a   Kim, Sang Ryong ^c  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Inflammation; Minocycline; Neurodegeneration; Prothrombin kringle 2

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MINOCYCLINE; PROTHROMBIN; TYROSINE 3 MONOOXYGENASE; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; CALCIUM BINDING PROTEIN; NEUROPROTECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DOPAMINERGIC NERVE CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; INSTITUTIONAL REVIEW; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ENCEPHALITIS; FEMALE; GENETICS; KRINGLE DOMAIN; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TOXICITY;

ANALYSIS OF VARIANCE; ANIMALS; CALCIUM-BINDING PROTEINS; DOPAMINERGIC NEURONS; ENCEPHALITIS; FEMALE; INTERLEUKIN-1BETA; KRINGLES; MICROFILAMENT PROTEINS; MINOCYCLINE; NEUROPROTECTIVE AGENTS; PROTHROMBIN; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 84907157658     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000122     Document Type: Article

References (29)

1. Liu B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J 2006; 8:E606-E662.
2. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, et al. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007; 38:646-651.
3. Kim SR, Chung ES, Bok E, Baik HH, Chung YC,Won SY, et al. Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res 2010; 88:1537-1548.
4. Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 2005; 95:1755-1765.
5. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22:1763-1771.
6. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J 2009; 23:739-750.
7. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6:797-801.
8. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 2002; 52:54-61.
9. Shikamoto Y, Morita T. Expression of factor X in both the rat brain and cells of the central nervous system. FEBS Lett 1999; 463:387-389.
10. Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, et al. Agrin and microvascular damage in Alzheimer's disease. Neurobiol Aging 2000; 21:349-355.
11. Furie KL, Rosenberg R, Thompson JL, Bauer K, Mohr JP, Rosner B, et al. Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. Neurology 2004; 63:777-784.
12. Won SY, Choi SH, Jin BK. Prothrombin kringle-2-induced oxidative stress contributes to the death of cortical neurons in vivo and in vitro: role of microglial NADPH oxidase. J Neuroimmunol 2009; 214:83-92.
13. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic Press; 1998.
14. Kim SR, Chen X, Oo TF, Kareva T, Yarygina O,Wang C, et al. Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 2011; 70:110-120.
15. Rhim TY, Park CS, Kim E, Kim SS. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun 1998; 252:513-516.
16. Dasgupta SK, Thiagarajan P. Inhibition of thrombin activity by prothrombin activation fragment 1.2. J Thromb Thrombolysis 2007; 24:157-162.
17. Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 1991; 6: 575-581.
18. Sokolova E, Reiser G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost 2008; 100:576-581.
19. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996; 211:13-16.
20. Klevenyi P, Andreassen O, Ferrante RJ, Schleicher JR Jr., Friedlander RM, Beal MF. Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 1999; 10:635-638.
21. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996; 72:355-363.
22. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999; 5:1403-1409.
23. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165:208-210.
24. Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, et al. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011; 18:79-88.
25. Ferger B, Leng A, Mura A, Hengerer B, Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNFsynthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 2004; 89:822-833.
26. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Trevino I, Blesch A, et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther 2011; 19:46-52.
27. Seidl SE, Potashkin JA. The promise of neuroprotective agents in Parkinson's disease. Front Neurol 2011; 2:68.
28. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 2006; 96:706-718.
29. Lee SM, Yune TY, Kim SJ, Kim YC, Oh YJ, Markelonis GJ, et al. Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J Neurochem 2004; 91:568-578.